Biogen Inc (BIIB)
308.88
0.00 (0.00%)
USD |
NASDAQ |
Jun 09, 16:00
331.30
+22.42
(+7.26%)
After-Hours: 20:00
Biogen Revenue (TTM): 10.10B for March 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
March 31, 2023 | 10.10B |
December 31, 2022 | 10.17B |
September 30, 2022 | 10.36B |
June 30, 2022 | 10.63B |
March 31, 2022 | 10.82B |
December 31, 2021 | 10.98B |
September 30, 2021 | 11.10B |
June 30, 2021 | 11.70B |
March 31, 2021 | 12.60B |
December 31, 2020 | 13.44B |
September 30, 2020 | 14.26B |
June 30, 2020 | 14.49B |
March 31, 2020 | 14.42B |
December 31, 2019 | 14.38B |
September 30, 2019 | 14.23B |
June 30, 2019 | 14.07B |
March 31, 2019 | 13.81B |
December 31, 2018 | 13.45B |
September 30, 2018 | 13.23B |
June 30, 2018 | 12.87B |
March 31, 2018 | 12.59B |
December 31, 2017 | 12.27B |
September 30, 2017 | 11.84B |
June 30, 2017 | 11.72B |
March 31, 2017 | 11.53B |
Date | Value |
---|---|
December 31, 2016 | 11.45B |
September 30, 2016 | 11.42B |
June 30, 2016 | 11.24B |
March 31, 2016 | 10.94B |
December 31, 2015 | 10.76B |
September 30, 2015 | 10.57B |
June 30, 2015 | 10.30B |
March 31, 2015 | 10.13B |
December 31, 2014 | 9.703B |
September 30, 2014 | 9.028B |
June 30, 2014 | 8.345B |
March 31, 2014 | 7.647B |
December 31, 2013 | 6.932B |
September 30, 2013 | 6.384B |
June 30, 2013 | 5.942B |
March 31, 2013 | 5.640B |
December 31, 2012 | 5.516B |
September 30, 2012 | 6.164B |
June 30, 2012 | 5.822B |
March 31, 2012 | 5.610B |
December 31, 2011 | 5.521B |
September 30, 2011 | 4.675B |
June 30, 2011 | 4.807B |
March 31, 2011 | 4.811B |
December 31, 2010 | 4.716B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
10.10B
Minimum
Mar 2023
14.49B
Maximum
Jun 2020
12.56B
Average
13.05B
Median
Revenue (TTM) Benchmarks
Eli Lilly and Co | 27.69B |
Johnson & Johnson | 96.26B |
Bristol-Myers Squibb Co | 45.85B |
Ionis Pharmaceuticals Inc | 575.97M |
Merck & Co Inc | 57.87B |